Detalles de la búsqueda
1.
As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.
Clin Infect Dis
; 67(2): 251-260, 2018 07 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29365083
2.
Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group.
PLoS One
; 18(2): e0281580, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36780493
3.
Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings.
J Acquir Immune Defic Syndr
; 94(2): 165-173, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37368929
4.
Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
J Int AIDS Soc
; 25(6): e25905, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36039892
5.
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Lancet HIV
; 6(9): e588-e600, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31371262
6.
7.
8.
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study
Artículo
en Inglés
| ARCA | ID: arc-36767
9.
Resultados
1 -
9
de 9
1
Próxima >
>>